Video
Dr. Infante on AM0010 in Patients With RCC
Author(s):
Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.
Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma (RCC).
AM0010 is a pegylated humanized IL-10 agonist that is developed to have increased exposure in the blood, Infante explains. Despite successes with PD-1/PD-L1 agents, there are several tumor types that do not have long-term responses with these therapies, demonstrating an ongoing and unmet need. This is also true in cancers that are not immune-sensitive, he adds.
In the phase I study, 33 patients were enrolled in dose-escalation cohorts, where solid tumor responses were observed in uveal melanoma and RCC. In an expansion cohort, researchers enrolled 18 more patients with RCC, totaling 19 patients who received 20 mg/kg of AM0010. Four patients did not go on to re-staging studies. Of these 15 patients, there were 4 total partial responses, Infante adds.
